Definium Therapeutics Inc (DFTX) Stock Price & News

DFTX:NASDAQ

Definium Therapeutics Inc

$35.09

-1.49%

(-0.53) 1D

$35.07

-0.06% (-0.020)

After hours

Closed: Oct 7, 4:00:01 PM GMT-4 · USD

All symbols

	Symbol	Price	Change	% Change

Generating top insights for DFTX...

Open

$35.34

High

$36.39

Low

$34.92

Mkt. cap

4.71B

Avg. vol.

2.23M

Volume

1.97M

52-wk high

$49.70

52-wk low

$14.62

EPS

-$3.43

Beta

2.19

Shares outstanding

134.37M

No. of employees

106

Open

$35.34

High

$36.39

Low

$34.92

Mkt. cap

4.71B

Avg. vol.

2.23M

Volume

1.97M

52-wk high

$49.70

52-wk low

$14.62

EPS

-$3.43

Beta

2.19

Shares outstanding

134.37M

No. of employees

106

Related stocks

Space Exploration Technologies Corp

News stories

From web sources and news partners

Stock Traders Daily

6 hours ago

The Technical Signals Behind (DFTX) That Institutions Follow

https://www.dars.gov.et/

2 months ago

DFTX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pipeline Investment Intensity - Quarterly Financial Update

Profile

Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs. Wikipedia

About Definium Therapeutics Inc

CEORobert Barrow

Employees106

Founded2010

Headquarters-

SectorPharmaceutical industry

Websitedefiniumtx.com

Analyst	Recommendation	Action	Price target	Projected	Date
Tazeen Ahmad Bank of America Securities	Buy	Maintained	$91.00	+159.3%	10/07/2026
Francois Brisebois LifeSci Capital	Buy	Maintained	$78.00	+122.3%	09/19/2026
Michael Okunewitch Maxim Group	Buy	Maintained	$55.00	+56.7%	09/15/2026
Paul Matteis Stifel Nicolaus	Buy	Maintained	$67.00	+90.9%	09/15/2026
Justin Walsh JonesTrading	Buy	Reiterated	$90.00	+156.5%	09/15/2026
Sumant Kulkarni Canaccord Genuity	Buy	Reiterated	$78.00	+122.3%	09/15/2026
Christopher Chen Robert W. Baird	Buy	Maintained	$79.00	+125.1%	09/15/2026
Jay Olson Oppenheimer	Buy	Maintained	$75.00	+113.7%	09/14/2026
Patrick Trucchio H.C. Wainwright	Buy	Reiterated	$70.00	+99.5%	09/15/2026
Ami Fadia Needham	Buy	Reiterated	$66.00	+88.1%	09/14/2026
Brian Abrahams RBC Capital	Buy	Maintained	$66.00	+88.1%	09/11/2026
Benjamin Burnett Wells Fargo	Buy	Maintained	$72.00	+105.2%	08/31/2026
David Amsellem Piper Sandler	Buy	Reiterated	$75.00	+113.7%	08/17/2026
Andrew Tsai Jefferies	Buy	Maintained	$65.00	+85.2%	08/13/2026
Unknown Analyst Evercore ISI	Buy	Maintained	$53.00	+51%	08/10/2026
Gavin Clark-Gartner Evercore ISI	Buy	Maintained	$26.00	-25.9%	03/02/2026
Rudy Li Wolfe Research	Buy	Initiated	$25.00	-28.8%	02/23/2026

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-
Cost of goods sold	-	-	-	-
Cost of revenue	-	-	-	-
Research and development expenses	30.98M	33.52M	41.48M	48.66M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	14.69M	14.06M	17.74M	26.41M
Operating expense	45.67M	47.58M	59.22M	75.08M
Total operating expenses	45.67M	47.58M	59.22M	75.08M
Operating income	-45.67M	-47.58M	-59.22M	-75.08M
Other non operating income	-22.54M	-5.06M	-20.05M	-86.23M
EBT including unusual items	-67.26M	-50.44M	-77.10M	-158.99M
EBT excluding unusual items	-67.26M	-50.44M	-77.10M	-158.99M
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-67.26M	-50.44M	-77.10M	-158.99M
Net profit margin	-	-	-	-
Earnings per share	-0.78	-	-	-1.44
Interest and investment income	2.26M	3.49M	3.46M	3.59M
Interest expense	-1.27M	-1.27M	-1.24M	-1.23M
Net interest expenses	988.00K	2.22M	2.21M	2.35M
Depreciation and amortization charges	-	-	-	-
EBITDA	-45.66M	-47.57M	-	-
Gain or loss from assets sale	-	-	-	-

Finance

Ask anything